ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,816 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselUltragenyx Europe GmbH
Ultragenyx Europe GmbH Logo
Verified· 2 sources

Ultragenyx Europe GmbH

Summary

About the company

Ultragenyx Europe GmbH is a biopharmaceutical company that develops therapies for rare and ultra-rare genetic diseases and researches multiple drug modalities, including gene therapy. The company maintains a clinical pipeline, provides approved medicines such as DOJOLVI and MEPSEVII, and operates patient support programs.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered6
Medicines for rare and ultra-rare genetic diseases
Drug development and marketing for rare and ultra-rare genetic diseases, including approved therapies and further treatment options across multiple indications.
Research and development programmes for rare diseases
Research programmes for rare and ultra-rare genetic diseases with biologics, small molecules, gene therapies and ASO approaches, as well as clinical study development.
Clinical studies
Clinical studies of investigational therapies, including participation information and references to ongoing studies for patients and physicians.
Patient access to therapies (UltraCare)
Patient programmes to support access to treatments, including help with insurance, financial support and patient assistance programmes.
Early access to investigational therapies
Early access to investigational therapies for certain patients with severe or immediately life-threatening disease, on a case-by-case basis and under certain conditions.

Knowledge

No knowledge articles yet

Once Ultragenyx Europe GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Ultragenyx Europe GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Ultragenyx Europe GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Ultragenyx Europe GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Lichtstrasse 35
4056 Basel

At a glance

Legal form
Limited Liability Company
UID
CHE-357.652.851
Founded
2024 · 2 years
Last commercial register change
December 18, 2025
Employees
11 to 20

Similar companies

NF
NOVARTIS FORSCHUNGSSTIFTUNG
Basel
NF
Novartis Foundation
Basel
NS
Novartis Stiftung für Mensch und Umwelt
Basel
IA
Intex-Biotech AG
Basel
LS
Latscha Schöllhorn Partner AG
Basel
TT
TOLREMO therapeutics AG
Basel
AS
Accense S.A.
Basel
EB
ESC Biotech Swiss AG
Basel